Abstract
Parkinson’s disease (PD) is one of the most common degenerative diseases of the human nervous system and has a wide range of serious impacts on human health and quality of life. Recently, research targeting high mobility group box 1 (HMGB1) in PD has emerged, and a variety of laboratory methods for inhibiting HMGB1 have achieved good results to a certain extent. However, given that HMGB1 undergoes a variety of intracellular modifications and three different forms of extracellular redox, the possible roles of these forms in PD are likely to be different. General inhibition of all forms of HMGB1 is obviously not ideal and has become one of the biggest obstacles in the clinical application of targeting HMGB1. In this review, pure mechanistic research of HMGB1 and in vivo research targeting HMGB1 were combined, the effects of HMGB1 on neurons and immune cell responses in PD are discussed in detail, and the problems that need to be focused on in the future are addressed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
All data are obtained from the published papers.
Code Availability
Not applicable.
References
Amato J, Cerofolini L, Brancaccio D, Giuntini S, Iaccarino N, Zizza P, Iachettini S, Biroccio A, Novellino E, Rosato A, Fragai M, Luchinat C, Randazzo A, Pagano B (2019) Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein. Nucleic Acids Res 47(18):9950–9966. https://doi.org/10.1093/nar/gkz727
Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560. https://doi.org/10.1001/jama.2019.22360
Aucott H, Lundberg J, Salo H, Klevenvall L, Damberg P, Ottosson L, Andersson U, Holmin S, Erlandsson Harris H (2018) Neuroinflammation in response to intracerebral injections of different HMGB1 redox isoforms. J Innate Immun 10(3):215–227. https://doi.org/10.1159/000487056
Bagheri V, Khorramdelazad H, Hassanshahi G, Moghadam-Ahmadi A, Vakilian A (2018) CXCL12 and CXCR4 in the peripheral blood of patients with Parkinson’s disease. NeuroImmunoModulation 25(4):201–205. https://doi.org/10.1159/000494435
Bhat SM, Massey N, Karriker LA, Singh B, Charavaryamath C (2019) Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling. Respir Res 20(1):27. https://doi.org/10.1186/s12931-019-0992-3
Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, Berman JW (2006) A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177(1–2):27–39. https://doi.org/10.1016/j.jneuroim.2006.05.003
Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 86(3):609–615. https://doi.org/10.1189/jlb.0908576
Cheng J, Liao Y, Dong Y, Hu H, Yang N, Kong X, Li S, Li X, Guo J, Qin L, Yu J, Ma C, Li J, Li M, Tang B, Yuan Z (2020) Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy 16(12):2193–2205. https://doi.org/10.1080/15548627.2020.1719723
Clarkson BD, Walker A, Harris MG, Rayasam A, Sandor M, Fabry Z (2015) CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression. J Immunol 194(2):531–541. https://doi.org/10.4049/jimmunol.1401320
Collaborators GBDN (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18(5):459–480. https://doi.org/10.1016/S1474-4422(18)30499-X
Das R, Chinnathambi S (2019) Microglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease. Cell Mol Life Sci 76(19):3681–3694. https://doi.org/10.1007/s00018-019-03132-2
Dave SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE (2009) Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 86(3):633–643. https://doi.org/10.1189/jlb.1008662
De Leo F, Quilici G, Tirone M, De Marchis F, Mannella V, Zucchelli C, Preti A, Gori A, Casalgrandi M, Mezzapelle R, Bianchi ME, Musco G (2019) Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment. EMBO Rep 20(10):e47788. https://doi.org/10.15252/embr.201947788
Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Hoglinger GU (2012) Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol 238(2):183–191. https://doi.org/10.1016/j.expneurol.2012.08.020
Ding S, Wang W, Wang X, Liang Y, Liu L, Ye Y, Yang J, Gao H, Zhuge Q (2016) Dopamine burden triggers neurodegeneration via production and release of TNF-alpha from astrocytes in minimal hepatic encephalopathy. Mol Neurobiol 53(8):5324–5343. https://doi.org/10.1007/s12035-015-9445-2
Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P (2007) The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81(1):84–91. https://doi.org/10.1189/jlb.0306171
Dzamko N, Gysbers A, Perera G, Bahar A, Shankar A, Gao J, Fu Y, Halliday GM (2017) Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol 133(2):303–319. https://doi.org/10.1007/s00401-016-1648-8
Enokido Y, Yoshitake A, Ito H, Okazawa H (2008) Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Commun 376(1):128–133. https://doi.org/10.1016/j.bbrc.2008.08.108
Flones IH, Fernandez-Vizarra E, Lykouri M, Brakedal B, Skeie GO, Miletic H, Lilleng PK, Alves G, Tysnes OB, Haugarvoll K, Dolle C, Zeviani M, Tzoulis C (2018) Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol 135(3):409–425. https://doi.org/10.1007/s00401-017-1794-7
Fritze D, Zhang W, Li JY, Chai B, Mulholland MW (2014) TNFalpha causes thrombin-dependent vagal neuron apoptosis in inflammatory bowel disease. J Gastrointest Surg 18(9):1632–1641. https://doi.org/10.1007/s11605-014-2573-6
Fu GX, Chen AF, Zhong Y, Zhao J, Gu YJ (2016) Decreased serum level of HMGB1 and MyD88 during human aging progress in healthy individuals. Aging Clin Exp Res 28(2):175–180. https://doi.org/10.1007/s40520-015-0402-8
Ghaffari S, Jang E, Naderinabi F, Sanwal R, Khosraviani N, Wang C, Steinberg BE, Goldenberg NM, Ikeda J, Lee WL (2021) Endothelial HMGB1 is a critical regulator of LDL transcytosis via an SREBP2-SR-BI axis. Arterioscler Thromb Vasc Biol 41(1):200–216. https://doi.org/10.1161/ATVBAHA.120.314557
Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493):985–989. https://doi.org/10.1126/science.290.5493.985
Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A, Hengerer B, Kassubek J, Ludolph AC, Weishaupt JH, Danzer KM (2014) Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients. Acta Neuropathol 128 (5):651-663https://doi.org/10.1007/s00401-014-1345-4
Guo X, Shi Y, Du P, Wang J, Han Y, Sun B, Feng J (2019) HMGB1/TLR4 promotes apoptosis and reduces autophagy of hippocampal neurons in diabetes combined with OSA. Life Sci 239:117020. https://doi.org/10.1016/j.lfs.2019.117020
Haga H, Matsuo K, Yabuki Y, Zhang C, Han F, Fukunaga K (2019) Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson’s disease. Neurochem Int 129:104492. https://doi.org/10.1016/j.neuint.2019.104492
Han X, Sun S, Sun Y, Song Q, Zhu J, Song N, Chen M, Sun T, Xia M, Ding J, Lu M, Yao H, Hu G (2019) Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy 15(11):1860–1881. https://doi.org/10.1080/15548627.2019.1596481
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9(4):325–338. https://doi.org/10.1038/nrd3003
Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG (2013) MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33(23):9592–9600. https://doi.org/10.1523/JNEUROSCI.5610-12.2013
Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, Liu Y, Qin H, Benveniste EN, Standaert DG (2018) Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp Neurol 300:179–187. https://doi.org/10.1016/j.expneurol.2017.11.010
He Y, Ding Y, Wang D, Zhang W, Chen W, Liu X, Qin W, Qian X, Chen H, Guo Z (2015) HMGB1 bound to cisplatin-DNA adducts undergoes extensive acetylation and phosphorylation in vivo. Chem Sci 6(3):2074–2078. https://doi.org/10.1039/c4sc03650f
Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 312(18):3526–3538. https://doi.org/10.1016/j.yexcr.2006.07.020
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565–581. https://doi.org/10.1038/s41582-019-0244-7
Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS, Hong JY, Pak YK, Kim YS, Hong JK, Hwang O, Jin BK (2011) Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease. J Immunol 187(2):960–969. https://doi.org/10.4049/jimmunol.1100009
Huttunen HJ, Fages C, Rauvala H (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274(28):19919–19924. https://doi.org/10.1074/jbc.274.28.19919
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106(6):518–526. https://doi.org/10.1007/s00401-003-0766-2
Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O (2015) Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 85(21):1834–1842. https://doi.org/10.1212/WNL.0000000000002151
Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A, Cadinanos J, Horner JW, Maratos-Flier E, Depinho RA (2011) Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469(7328):102–106. https://doi.org/10.1038/nature09603
Kaur C, Sivakumar V, Zou Z, Ling EA (2014) Microglia-derived proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1beta induce Purkinje neuronal apoptosis via their receptors in hypoxic neonatal rat brain. Brain Struct Funct 219(1):151–170. https://doi.org/10.1007/s00429-012-0491-5
Kim YM, Park EJ, Kim JH, Park SW, Kim HJ, Chang KC (2016) Ethyl pyruvate inhibits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages. Int Immunopharmacol 41:98–105. https://doi.org/10.1016/j.intimp.2016.11.002
Kim SJ, Ryu MJ, Han J, Jang Y, Kim J, Lee MJ, Ryu I, Ju X, Oh E, Chung W, Kweon GR, Heo JY (2017) Activation of the HMGB1-RAGE axis upregulates TH expression in dopaminergic neurons via JNK phosphorylation. Biochem Biophys Res Commun 493(1):358–364. https://doi.org/10.1016/j.bbrc.2017.09.017
Kim SJ, Ryu MJ, Han J, Jang Y, Lee MJ, Ju X, Ryu I, Lee YL, Oh E, Chung W, Heo JY, Kweon GR (2019) Non-cell autonomous modulation of tyrosine hydroxylase by HMGB1 released from astrocytes in an acute MPTP-induced Parkinsonian mouse model. Lab Invest 99(9):1389–1399. https://doi.org/10.1038/s41374-019-0254-5
Kohlstaedt LA, King DS, Cole RD (1986) Native state of high mobility group chromosomal proteins 1 and 2 is rapidly lost by oxidation of sulfhydryl groups during storage. Biochemistry 25(16):4562–4565. https://doi.org/10.1021/bi00364a016
Kohlstaedt LA, Sung EC, Fujishige A, Cole RD (1987) Non-histone chromosomal protein HMG1 modulates the histone H1-induced condensation of DNA. J Biol Chem 262(2):524–526
Kraft AD, McPherson CA, Harry GJ (2009) Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology 30(5):785–793. https://doi.org/10.1016/j.neuro.2009.07.001
Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, Yang H (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9(1–2):37–45
Li Y, Niu M, Zhao A, Kang W, Chen Z, Luo N, Zhou L, Zhu X, Lu L, Liu J (2019) CXCL12 is involved in alpha-synuclein-triggered neuroinflammation of Parkinson’s disease. J Neuroinflammation 16(1):263. https://doi.org/10.1186/s12974-019-1646-6
Lindersson EK, Hojrup P, Gai WP, Locker D, Martin D, Jensen PH (2004) Alpha-synuclein filaments bind the transcriptional regulator HMGB-1. NeuroReport 15(18):2735–2739
Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, Cao L, Tang D, Duan X (2014) MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy 10(3):442–452. https://doi.org/10.4161/auto.27418
Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ, Wang H (2014) Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol 10(6):713–727
Luo XG, Zhang JJ, Zhang CD, Liu R, Zheng L, Wang XJ, Chen SD, Ding JQ (2010) Altered regulation of CD200 receptor in monocyte-derived macrophages from individuals with Parkinson’s disease. Neurochem Res 35(4):540–547. https://doi.org/10.1007/s11064-009-0094-6
Lv R, Du L, Liu X, Zhou F, Zhang Z, Zhang L (2019) Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-kappaB signaling pathway in a mouse model of Parkinson’s disease. Life Sci 223:158–165. https://doi.org/10.1016/j.lfs.2019.03.030
Mandke P, Vasquez KM (2019) Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: implications in DNA repair and immune responses. DNA Repair 83:102701. https://doi.org/10.1016/j.dnarep.2019.102701
Milanese C, Cerri S, Ulusoy A, Gornati SV, Plat A, Gabriels S, Blandini F, Di Monte DA, Hoeijmakers JH, Mastroberardino PG (2018) Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease. Cell Death Dis 9(8):818. https://doi.org/10.1038/s41419-018-0848-7
Mitsouras K, Wong B, Arayata C, Johnson RC, Carey M (2002) The DNA architectural protein HMGB1 displays two distinct modes of action that promote enhanceosome assembly. Mol Cell Biol 22(12):4390–4401. https://doi.org/10.1128/mcb.22.12.4390-4401.2002
Musgrove RE, Helwig M, Bae EJ, Aboutalebi H, Lee SJ, Ulusoy A, Di Monte DA (2019) Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular alpha-synuclein transfer. J Clin Invest 129(9):3738–3753. https://doi.org/10.1172/JCI127330
Musumeci D, Roviello GN, Montesarchio D (2014) An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 141(3):347–357. https://doi.org/10.1016/j.pharmthera.2013.11.001
Nazari S, Rameshrad M, Hosseinzadeh H (2017) Toxicological effects of glycyrrhiza glabra (Licorice): a review. Phytother Res 31(11):1635–1650. https://doi.org/10.1002/ptr.5893
Nishibori M, Mori S, Takahashi HK (2019) Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. J Pharmacol Sci 140(1):94–101. https://doi.org/10.1016/j.jphs.2019.04.006
Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR (2018) MPTP-induced parkinsonism: an historical case series. Lancet Neurol 17(4):300–301. https://doi.org/10.1016/S1474-4422(18)30072-3
Nonnekes J, Ruzicka E, Nieuwboer A, Hallett M, Fasano A, Bloem BR (2019) Compensation strategies for gait impairments in Parkinson disease: a review. JAMA Neurol 76(6):718–725. https://doi.org/10.1001/jamaneurol.2019.0033
Palmblad K, Schierbeck H, Sundberg E, Horne AC, Harris HE, Henter JI, Antoine DJ, Andersson U (2015) High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med 20:538–547. https://doi.org/10.2119/molmed.2014.00183
Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284(4):C870-879. https://doi.org/10.1152/ajpcell.00322.2002
Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279(9):7370–7377. https://doi.org/10.1074/jbc.M306793200
Pashenkov M, Soderstrom M, Link H (2003) Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. J Neuroimmunol 135(1–2):154–160. https://doi.org/10.1016/s0165-5728(02)00441-1
Pellegrini L, Foglio E, Pontemezzo E, Germani A, Russo MA, Limana F (2019) HMGB1 and repair: focus on the heart. Pharmacol Ther 196:160–182. https://doi.org/10.1016/j.pharmthera.2018.12.005
Peng H, Erdmann N, Whitney N, Dou H, Gorantla S, Gendelman HE, Ghorpade A, Zheng J (2006) HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia 54(6):619–629. https://doi.org/10.1002/glia.20409
Polanska E, Dobsakova Z, Dvorackova M, Fajkus J, Stros M (2012) HMGB1 gene knockout in mouse embryonic fibroblasts results in reduced telomerase activity and telomere dysfunction. Chromosoma 121(4):419–431. https://doi.org/10.1007/s00412-012-0373-x
Qi ML, Tagawa K, Enokido Y, Yoshimura N, Wada Y, Watase K, Ishiura S, Kanazawa I, Botas J, Saitoe M, Wanker EE, Okazawa H (2007) Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 9(4):402–414. https://doi.org/10.1038/ncb1553
Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, Zhang X, Xue Y, Maimon R, Dowdy SF, Devaraj NK, Zhou Z, Mobley WC, Cleveland DW, Fu XD (2020) Reversing a model of Parkinson’s disease with in situ converted nigral neurons. Nature 582(7813):550–556. https://doi.org/10.1038/s41586-020-2388-4
Richard SA, Jiang Y, Xiang LH, Zhou S, Wang J, Su Z, Xu H (2017) Post-translational modifications of high mobility group box 1 and cancer. Am J Transl Res 9(12):5181–5196
Robinson AP, Caldis MW, Harp CT, Goings GE, Miller SD (2013) High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J Autoimmun 43:32–43. https://doi.org/10.1016/j.jaut.2013.02.005
Rosciszewski G, Cadena V, Auzmendi J, Cieri MB, Lukin J, Rossi AR, Murta V, Villarreal A, Reines A, Gomes FCA, Ramos AJ (2019) Detrimental effects of HMGB-1 require microglial-astroglial interaction: implications for the status epilepticus -induced neuroinflammation. Front Cell Neurosci 13:380. https://doi.org/10.3389/fncel.2019.00380
Santoro M, Maetzler W, Stathakos P, Martin HL, Hobert MA, Rattay TW, Gasser T, Forrester JV, Berg D, Tracey KJ, Riedel G, Teismann P (2016) In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson’s disease which can be attenuated by glycyrrhizin. Neurobiol Dis 91:59–68. https://doi.org/10.1016/j.nbd.2016.02.018
Sasaki T, Liu K, Agari T, Yasuhara T, Morimoto J, Okazaki M, Takeuchi H, Toyoshima A, Sasada S, Shinko A, Kondo A, Kameda M, Miyazaki I, Asanuma M, Borlongan CV, Nishibori M, Date I (2016) Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson’s disease. Exp Neurol 275(Pt 1):220–231. https://doi.org/10.1016/j.expneurol.2015.11.003
Satpute R, Lomash V, Kaushal M, Bhattacharya R (2013) Neuroprotective effects of alpha-ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in mice. Hum Exp Toxicol 32(7):747–758. https://doi.org/10.1177/0960327112468172
Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, Uguccioni M (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209(3):551–563. https://doi.org/10.1084/jem.20111739
Seo MS, Kim HJ, Kim H, Park SW (2019) Ethyl pyruvate directly attenuates active secretion of HMGB1 in proximal tubular cells via induction of heme oxygenase-1. J Clin Med https://doi.org/10.3390/jcm8050629
Shaltiel-Karyo R, Frenkel-Pinter M, Rockenstein E, Patrick C, Levy-Sakin M, Schiller A, Egoz-Matia N, Masliah E, Segal D, Gazit E (2013) A blood-brain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J Biol Chem 288(24):17579–17588. https://doi.org/10.1074/jbc.M112.434787
Shimoji M, Pagan F, Healton EB, Mocchetti I (2009) CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox Res 16(3):318–328. https://doi.org/10.1007/s12640-009-9076-3
Shin JH, Kim ID, Kim SW, Lee HK, Jin Y, Park JH, Kim TK, Suh CK, Kwak J, Lee KH, Han PL, Lee JK (2015) Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium. Mol Med 20:649–657. https://doi.org/10.2119/molmed.2014.00039
Sofiadis K, Josipovic N, Nikolic M, Kargapolova Y, Ubelmesser N, Varamogianni-Mamatsi V, Zirkel A, Papadionysiou I, Loughran G, Keane J, Michel A, Gusmao EG, Becker C, Altmuller J, Georgomanolis T, Mizi A, Papantonis A (2021) HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence. Mol Syst Biol 17(6):e9760. https://doi.org/10.15252/msb.20209760
Soh S, Jun JH, Song JW, Shin EJ, Kwak YL, Shim JK (2018) Ethyl pyruvate attenuates myocardial ischemia-reperfusion injury exacerbated by hyperglycemia via retained inhibitory effect on HMGB1. Int J Cardiol 252:156–162. https://doi.org/10.1016/j.ijcard.2017.11.038
Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, Zhang HQ, Li M (2014) HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy 10(1):144–154. https://doi.org/10.4161/auto.26751
Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R, Shahani N, Tyagi R, Snyder SH, Usiello A (2011) Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci 15(2):191–193. https://doi.org/10.1038/nn.2994
Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133–150. https://doi.org/10.1038/nrneurol.2017.188
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ 3rd, Lotze MT (2010) Endogenous HMGB1 regulates autophagy. J Cell Biol 190(5):881–892. https://doi.org/10.1083/jcb.200911078
Teismann P, Sathe K, Bierhaus A, Leng L, Martin HL, Bucala R, Weigle B, Nawroth PP, Schulz JB (2012) Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 33(10):2478–2490. https://doi.org/10.1016/j.neurobiolaging.2011.12.006
Tian Y, Cao Y, Chen R, Jing Y, Xia L, Zhang S, Xu H, Su Z (2020) HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson’s disease model. Clin Sci 134(15):2075–2090. https://doi.org/10.1042/CS20200553
Tirone M, Tran NL, Ceriotti C, Gorzanelli A, Canepari M, Bottinelli R, Raucci A, Di Maggio S, Santiago C, Mellado M, Saclier M, Francois S, Careccia G, He M, De Marchis F, Conti V, Ben Larbi S, Cuvellier S, Casalgrandi M, Preti A, Chazaud B, Al-Abed Y, Messina G, Sitia G, Brunelli S, Bianchi ME, Venereau E (2018) High mobility group box 1 orchestrates tissue regeneration via CXCR4. J Exp Med 215(1):303–318. https://doi.org/10.1084/jem.20160217
Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grunewald A, Almuammar S, Konig IR, Lill CM, Lohmann K, Klein C, Marras C (2018) Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33(12):1857–1870. https://doi.org/10.1002/mds.27527
Urbonaviciute V, Meister S, Furnrohr BG, Frey B, Guckel E, Schett G, Herrmann M, Voll RE (2009) Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 42(4):305–307. https://doi.org/10.1080/08916930902831803
Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, Shams SS, Yang H, Varani L, Andersson U, Tracey KJ, Bachi A, Uguccioni M, Bianchi ME (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209(9):1519–1528. https://doi.org/10.1084/jem.20120189
Venereau E, Schiraldi M, Uguccioni M, Bianchi ME (2013) HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol 55(1):76–82. https://doi.org/10.1016/j.molimm.2012.10.037
Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N (2017) Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol Neurodegener 12(1):52. https://doi.org/10.1186/s13024-017-0195-7
Wang X, Chen S, Ma G, Ye M, Lu G (2005) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 126(12):1241–1254. https://doi.org/10.1016/j.mad.2005.06.012
Wang CY, Kao TC, Lo WH, Yen GC (2011) Glycyrrhizic acid and 18beta-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-kappaB through PI3K p110delta and p110gamma inhibitions. J Agric Food Chem 59(14):7726–7733. https://doi.org/10.1021/jf2013265
Wang H, Ward MF, Sama AE (2014) Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets 18(3):257–268. https://doi.org/10.1517/14728222.2014.863876
Wang K, Huang J, Xie W, Huang L, Zhong C, Chen Z (2016) Beclin1 and HMGB1 ameliorate the alpha-synuclein-mediated autophagy inhibition in PC12 cells. Diagn Pathol 11:15. https://doi.org/10.1186/s13000-016-0459-5
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS (2021) CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson disease. Brain. https://doi.org/10.1093/brain/awab103
Wlodarczyk A, Lobner M, Cedile O, Owens T (2014) Comparison of microglia and infiltrating CD11c(+) cells as antigen presenting cells for T cell proliferation and cytokine response. J Neuroinflammation 11:57. https://doi.org/10.1186/1742-2094-11-57
Wolf Y, Shemer A, Levy-Efrati L, Gross M, Kim JS, Engel A, David E, Chappell-Maor L, Grozovski J, Rotkopf R, Biton I, Eilam-Altstadter R, Jung S (2018) Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced demyelination. Eur J Immunol 48(8):1308–1318. https://doi.org/10.1002/eji.201847540
Wu AH, He L, Long W, Zhou Q, Zhu S, Wang P, Fan S, Wang H (2015a) Novel mechanisms of herbal therapies for inhibiting HMGB1 secretion or action. Evid Based Complementary Altern Med 2015:1-11
Wu CH, Chen AZ, Yen GC (2015b) Protective effects of glycyrrhizic acid and 18beta-glycyrrhetinic acid against cisplatin-induced nephrotoxicity in BALB/c mice. J Agric Food Chem 63(4):1200–1209. https://doi.org/10.1021/jf505471a
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101(1):296–301. https://doi.org/10.1073/pnas.2434651100
Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107(26):11942–11947. https://doi.org/10.1073/pnas.1003893107
Yang H, Wang H, Chavan SS, Andersson U (2015a) High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol Med 21(Suppl 1):S6–S12. https://doi.org/10.2119/molmed.2015.00087
Yang H, Wang H, Ju Z, Ragab AA, Lundback P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y (2015b) MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212(1):5–14. https://doi.org/10.1084/jem.20141318
Yang Y, Han C, Guo L, Guan Q (2018) High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson’s disease and the relationship of pathological staging. Brain Behav 8(4):e00948. https://doi.org/10.1002/brb3.948
Ypinga JHL, de Vries NM, Boonen L, Koolman X, Munneke M, Zwinderman AH, Bloem BR (2018) Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol 17(2):153–161. https://doi.org/10.1016/S1474-4422(17)30406-4
Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, Iwahara J (2013) Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem 288(17):11621–11627. https://doi.org/10.1074/jbc.M113.449942
Zhang J, Niu N, Wang M, McNutt MA, Zhang D, Zhang B, Lu S, Liu Y, Liu Z (2013) Neuron-derived IgG protects dopaminergic neurons from insult by 6-OHDA and activates microglia through the FcgammaR I and TLR4 pathways. Int J Biochem Cell Biol 45(8):1911–1920. https://doi.org/10.1016/j.biocel.2013.06.005
Zhang Y, Karki R, Igwe OJ (2015) Toll-like receptor 4 signaling: a common pathway for interactions between prooxidants and extracellular disulfide high mobility group box 1 (HMGB1) protein-coupled activation. Biochem Pharmacol 98(1):132–143. https://doi.org/10.1016/j.bcp.2015.08.109
Zhao X, Rouhiainen A, Li Z, Guo S, Rauvala H (2020) Regulation of neurogenesis in mouse brain by HMGB1. Cells 9 (7). https://doi.org/10.3390/cells9071714
Acknowledgements
We thank the Springer Nature Author Services editing the revision.
Funding
This work was supported by Jiangsu Province “333” project (NO BRA2018016), Primary Research and Development Plan of Jiangsu Province (NO BE2019700), Six talent peaks project in Jiangsu Province (NO 2019-WSN-122), Projects of International Cooperation from Jiangsu (BX2019100), International cooperation and exchange from Zhenjiang (GJ2020010), and Graduate student scientific research innovation projects in Jiangsu province (KYCX18-2283).
Author information
Authors and Affiliations
Contributions
YT collected information from literatures and wrote the draft. RC read and edited the draft. ZS provided the idea and grant and revised the draft.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical Approval
Not applicable.
Consent to Participate
Not applicable.
Consent for Publication
All authors approved the final version of the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tian, Y., Chen, R. & Su, Z. HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease. Cell Mol Neurobiol 43, 47–58 (2023). https://doi.org/10.1007/s10571-021-01170-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-021-01170-8